AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence.

“Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology to discover new medicines faster.

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the ...

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier ...